NCT04140448View on ClinicalTrials.gov

Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion

RecruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

October 9, 2023

Primary Completion Date

October 30, 2024

Study Completion Date

December 15, 2025

Conditions
Retinal Vein OcclusionMacular Edema
Interventions
DRUG

Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]

Intravitreal injection of Ranibizumab 0.5 MG/0.05 ML

DEVICE

Ultra-wide Fluorescein Angiography

Ultra-wide-field Fluorescein Angiography can clearly observe the peripheral retina

Trial Locations (1)

430060

RECRUITING

Renmin Hospital of Wuhan University, Wuhan

All Listed Sponsors
lead

Renmin Hospital of Wuhan University

OTHER